99 related articles for article (PubMed ID: 7504138)
1. Activation of complement by Fluosol attributable to the pluronic detergent micelle structure.
Ingram DA; Forman MB; Murray JJ
J Cardiovasc Pharmacol; 1993 Sep; 22(3):456-61. PubMed ID: 7504138
[TBL] [Abstract][Full Text] [Related]
2. Phagocytic activation of human neutrophils by the detergent component of fluosol.
Ingram DA; Forman MB; Murray JJ
Am J Pathol; 1992 May; 140(5):1081-7. PubMed ID: 1316083
[TBL] [Abstract][Full Text] [Related]
3. Role of perfluorochemical emulsions in the treatment of myocardial reperfusion injury.
Forman MB; Ingram DA; Murray JJ
Am Heart J; 1992 Nov; 124(5):1347-57. PubMed ID: 1442506
[TBL] [Abstract][Full Text] [Related]
4. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis.
Vercellotti GM; Hammerschmidt DE; Craddock PR; Jacob HS
Blood; 1982 Jun; 59(6):1299-1304. PubMed ID: 7082830
[TBL] [Abstract][Full Text] [Related]
5. Complement activation by artificial blood substitute Fluosol: in vitro and in vivo studies.
Hong F; Shastri KA; Logue GL; Spaulding MB
Transfusion; 1991 Sep; 31(7):642-7. PubMed ID: 1909821
[TBL] [Abstract][Full Text] [Related]
6. Limitation of complement activation by perfluorocarbon emulsions: superiority of lecithin-emulsified preparations.
Hammerschmidt DE; Vercellotti GM
Biomater Artif Cells Artif Organs; 1988; 16(1-3):431-8. PubMed ID: 3263156
[TBL] [Abstract][Full Text] [Related]
7. Prevention of neutrophil-mediated injury to endothelial cells by perfluorochemical.
Babbitt DG; Forman MB; Jones R; Bajaj AK; Hoover RL
Am J Pathol; 1990 Feb; 136(2):451-9. PubMed ID: 2407126
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion.
Forman MB; Pitarys CJ; Vildibill HD; Lambert TL; Ingram DA; Virmani R; Murray JJ
J Am Coll Cardiol; 1992 Jan; 19(1):205-16. PubMed ID: 1729335
[TBL] [Abstract][Full Text] [Related]
9. Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute.
Lane TA; Lamkin GE
Blood; 1986 Aug; 68(2):351-4. PubMed ID: 3524707
[TBL] [Abstract][Full Text] [Related]
10. Side reaction caused by the perfluorocarbon emulsions in intravenous infusion to experimental animals.
Sedova LA; Kochetygov NI; Berkos MV; Pjatowskaja NN
Artif Cells Blood Substit Immobil Biotechnol; 1998 Mar; 26(2):149-57. PubMed ID: 9564433
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic effects of intravenous lecithin-based perfluorocarbon emulsions in dogs.
Mattrey RF; Hilpert PL; Long CD; Long DM; Mitten RM; Peterson T
Crit Care Med; 1989 Jul; 17(7):652-6. PubMed ID: 2736927
[TBL] [Abstract][Full Text] [Related]
12. Extended use of Fluosol emulsion in acute myocardial ischemia treatment.
Ohyanagi H; Saitoh Y; Uchida T; Watanabe M; Yamanouchi K; Yokoyama K; Mitsuno T
Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):941-9. PubMed ID: 1391538
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phospholipase A2 activity by Fluosol, an artificial blood substitute.
Shakir KM; Williams TJ
Prostaglandins; 1982 Jun; 23(6):919-27. PubMed ID: 7122911
[TBL] [Abstract][Full Text] [Related]
14. Hyperoxic reperfusion is required to reduce infarct size after intravenous therapy with perfluorochemical (Fluosol-DA 20%) or its detergent component (poloxamer 188) in a poorly collateralized animal model. Absence of a role of polymorphonuclear leukocytes.
Kolodgie FD; Farb A; Carlson GC; Wilson PS; Virmani R
J Am Coll Cardiol; 1994 Oct; 24(4):1098-108. PubMed ID: 7930204
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluosol-DA infusion on pulmonary vascular permeability in the dog lung.
Hall JE; Ehrhart IC; Hofman WF
J Trauma; 1986 May; 26(5):432-7. PubMed ID: 3084806
[TBL] [Abstract][Full Text] [Related]
16. Dissociation of ST segment elevation and regional wall motion with open-artery, intracoronary Fluosol.
Schaer GL; Krucoff MW; Green C; Visner MS
Am Heart J; 1989 Oct; 118(4):679-85. PubMed ID: 2529747
[TBL] [Abstract][Full Text] [Related]
17. Protection against ischemia during prolonged balloon inflation by distal coronary perfusion with use of an autoperfusion catheter or Fluosol.
Robalino BD; Marwick T; Lafont A; Vaska K; Whitlow PL
J Am Coll Cardiol; 1992 Nov; 20(6):1378-84. PubMed ID: 1430688
[TBL] [Abstract][Full Text] [Related]
18. [Influences of Fluosol-DA infusion on the complement activation and on the blood level of histamine in man].
Fukushima K; Nakamura M; Hinuma K
Masui; 1983 Feb; 32(2):192-8. PubMed ID: 6854932
[No Abstract] [Full Text] [Related]
19. The effect of Fluosol-DA on induction of inhalation anesthesia.
Chilcoat RT; Gerson JI; Allen FB; Mapleson WW
Anesth Analg; 1985 Apr; 64(4):405-10. PubMed ID: 3985389
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the Arthus reaction and suppression of delayed type hypersensitivity (DTH) by pluronic F-68, a detergent frequently used to prepare perfluorocarbon emulsions.
Triolo AJ; Osterholm JL; Kratky MT
Int J Immunopharmacol; 1989; 11(3):241-8. PubMed ID: 2525535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
